Literature DB >> 25150568

Pharmacological treatment of obsessive-compulsive disorder.

Christopher Pittenger1, Michael H Bloch2.   

Abstract

Obsessive-compulsive disorder (OCD) affects up to 2.5% of the population of the course of a lifetime and produces substantial morbidity. Approximately 70% of patients can experience significant symptomatic relief with appropriate pharmacotherapy. Selective serotonin reuptake inhibitors are the mainstay of pharmacological treatment. These drugs are typically used at higher doses and for longer periods than in depression. Proven second-line treatments include the tricyclic clomipramine and the addition of low-dose neuroleptic medications. OCD refractory to available treatments remains a profound clinical challenge.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressant; Augmentation; OCD; Obsessive-compulsive disorder; Pharmacotherapy; SSRI

Mesh:

Substances:

Year:  2014        PMID: 25150568      PMCID: PMC4143776          DOI: 10.1016/j.psc.2014.05.006

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  72 in total

1.  Memantine for treatment-resistant OCD.

Authors:  Michael Poyurovsky; Ronit Weizman; Abraham Weizman; Lorrin Koran
Journal:  Am J Psychiatry       Date:  2005-11       Impact factor: 18.112

2.  Escitalopram prevents relapse of obsessive-compulsive disorder.

Authors:  Naomi A Fineberg; Brigitte Tonnoir; Ole Lemming; Dan J Stein
Journal:  Eur Neuropsychopharmacol       Date:  2007-01-19       Impact factor: 4.600

3.  Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.

Authors:  David L Walker; Kerry J Ressler; Kwok-Tung Lu; Michael Davis
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

4.  Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.

Authors:  Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

Review 5.  Glutamate receptors in extinction and extinction-based therapies for psychiatric illness.

Authors:  Karyn M Myers; William A Carlezon; Michael Davis
Journal:  Neuropsychopharmacology       Date:  2010-07-14       Impact factor: 7.853

6.  Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.

Authors:  Ali Ghaleiha; Neda Entezari; Amirhossein Modabbernia; Babak Najand; Neda Askari; Mina Tabrizi; Mandana Ashrafi; Reza Hajiaghaee; Shahin Akhondzadeh
Journal:  J Psychiatr Res       Date:  2012-10-09       Impact factor: 4.791

7.  Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults.

Authors:  William M Greenberg; Melissa M Benedict; Joanna Doerfer; Megan Perrin; Laura Panek; W Louis Cleveland; Daniel C Javitt
Journal:  J Psychiatr Res       Date:  2008-11-30       Impact factor: 4.791

8.  Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.

Authors:  Jamie D Feusner; Lauren Kerwin; Sanjaya Saxena; Alexander Bystritsky
Journal:  Psychopharmacol Bull       Date:  2009

9.  Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.

Authors:  Donatella Marazziti; Francesca Golia; Giorgio Consoli; Silvio Presta; Chiara Pfanner; Marina Carlini; Francesco Mungai; Mario Catena Dell'osso
Journal:  CNS Spectr       Date:  2008-11       Impact factor: 3.790

10.  Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline.

Authors:  T R Insel; D L Murphy; R M Cohen; I Alterman; C Kilts; M Linnoila
Journal:  Arch Gen Psychiatry       Date:  1983-06
View more
  17 in total

1.  OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding.

Authors:  Christopher Pittenger; Thomas G Adams; Jean-Dominique Gallezot; Michael J Crowley; Nabeel Nabulsi; Hong Gao; Stephen A Kichuk; Ryan Simpson; Eileen Billingslea; Jonas Hannestad; Michael Bloch; Linda Mayes; Zubin Bhagwagar; Richard E Carson
Journal:  J Affect Disord       Date:  2016-02-09       Impact factor: 4.839

2.  Variability and anatomical specificity of the orbitofrontothalamic fibers of passage in the ventral capsule/ventral striatum (VC/VS): precision care for patient-specific tractography-guided targeting of deep brain stimulation (DBS) in obsessive compulsive disorder (OCD).

Authors:  Nikolaos Makris; Yogesh Rathi; Palig Mouradian; Giorgio Bonmassar; George Papadimitriou; Wingkwai I Ing; Edward H Yeterian; Marek Kubicki; Emad N Eskandar; Lawrence L Wald; Qiuyun Fan; Aapo Nummenmaa; Alik S Widge; Darin D Dougherty
Journal:  Brain Imaging Behav       Date:  2016-12       Impact factor: 3.978

Review 3.  The prefrontal cortex and neurosurgical treatment for intractable OCD.

Authors:  Steven A Rasmussen; Wayne K Goodman
Journal:  Neuropsychopharmacology       Date:  2021-08-25       Impact factor: 7.853

Review 4.  Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder.

Authors:  Reilly R Kayser
Journal:  J Clin Psychiatry       Date:  2020-09-08       Impact factor: 4.384

5.  Glutamatergic agents for OCD and related disorders.

Authors:  Christopher Pittenger
Journal:  Curr Treat Options Psychiatry       Date:  2015-09

6.  Glutamate modulators in the treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger
Journal:  Psychiatr Ann       Date:  2015-06

7.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225

Review 8.  Functional Evaluations of Genes Disrupted in Patients with Tourette's Disorder.

Authors:  Nawei Sun; Jay A Tischfield; Robert A King; Gary A Heiman
Journal:  Front Psychiatry       Date:  2016-02-09       Impact factor: 4.157

9.  Long-term consequences of chronic fluoxetine exposure on the expression of myelination-related genes in the rat hippocampus.

Authors:  Y Kroeze; D Peeters; F Boulle; J L Pawluski; D L A van den Hove; H van Bokhoven; H Zhou; J R Homberg
Journal:  Transl Psychiatry       Date:  2015-09-22       Impact factor: 6.222

10.  Impact of dissociation on treatment of depressive and anxiety spectrum disorders with and without personality disorders.

Authors:  Jan Prasko; Ales Grambal; Petra Kasalova; Dana Kamardova; Marie Ociskova; Michaela Holubova; Kristyna Vrbova; Zuzana Sigmundova; Klara Latalova; Milos Slepecky; Marta Zatkova
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-17       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.